(SBS) Companhia de Saneamento - Overview
Exchange: NYSE •
Country: Brazil •
Currency: USD •
Type: Common Stock •
ISIN: US20441A1025
Stock: Water, Sewage, Sanitation
Total Rating 49
Risk 37
Buy Signal -0.34
| Risk 5d forecast | |
|---|---|
| Volatility | 34.5% |
| Relative Tail Risk | -1.22% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.83 |
| Alpha | 65.88 |
| Character TTM | |
|---|---|
| Beta | 0.661 |
| Beta Downside | 0.101 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.79% |
| CAGR/Max DD | 1.97 |
EPS (Earnings per Share)
Revenue
Description: SBS Companhia de Saneamento March 03, 2026
Companhia de Saneamento Básico do Estado de São Paulo (SABESP) is a major Brazilian utility provider specializing in water supply and sewage collection across 375 municipalities in São Paulo State. The company operates a regulated business model where revenue is generated through long-term concession agreements and wholesale service contracts. Headquartered in São Paulo, the firm manages millions of individual connections, providing critical infrastructure to one of South Americas most densely populated regions.
The water utility sector typically benefits from high barriers to entry and inelastic demand, as these services are essential for public health and urban development. SABESP’s operations are subject to regional regulatory frameworks that determine tariff adjustments based on operational costs and capital expenditure requirements. For a deeper look into the companys valuation metrics, consider reviewing the latest data on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 8.03b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA -22.60 > 1.0 |
| NWC/Revenue: -4.80% < 20% (prev 0.51%; Δ -5.31% < -1%) |
| CFO/TA 0.11 > 3% & CFO 10.12b > Net Income 8.03b |
| Net Debt (29.96b) to EBITDA (14.69b): 2.04 < 3 |
| Current Ratio: 0.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (683.1m) vs 12m ago -0.08% < -2% |
| Gross Margin: 35.31% > 18% (prev 0.55%; Δ 3476 % > 0.5%) |
| Asset Turnover: 74.75% > 50% (prev 249.0%; Δ -174.2% > 0%) |
| Interest Coverage Ratio: 13.49 > 6 (EBITDA TTM 14.69b / Interest Expense TTM 958.4m) |
Altman Z'' 2.90
| A: -0.02 (Total Current Assets 12.56b - Total Current Liabilities 14.53b) / Total Assets 95.99b |
| B: 0.19 (Retained Earnings 18.25b / Total Assets 95.99b) |
| C: 0.23 (EBIT TTM 12.93b / Avg Total Assets 55.14b) |
| D: 0.80 (Book Value of Equity 42.71b / Total Liabilities 53.28b) |
| Altman-Z'' Score: 2.90 = A |
Beneish M 0.95
| DSRI: 5.14 (Receivables 4.48b/753.3m, Revenue 41.21b/35.57b) |
| GMI: 1.55 (GM 35.31% / 54.67%) |
| AQI: 0.97 (AQ_t 0.86 / AQ_t-1 0.89) |
| SGI: 1.16 (Revenue 41.21b / 35.57b) |
| TATA: -0.02 (NI 8.03b - CFO 10.12b) / TA 95.99b) |
| Beneish M-Score: 0.95 (Cap -4..+1) = D |
What is the price of SBS shares?
As of March 07, 2026, the stock is trading at USD 27.56 with a total of 1,607,652 shares traded.
Over the past week, the price has changed by -8.16%, over one month by -0.11%, over three months by +11.96% and over the past year by +78.74%.
Over the past week, the price has changed by -8.16%, over one month by -0.11%, over three months by +11.96% and over the past year by +78.74%.
Is SBS a buy, sell or hold?
Companhia de Saneamento has received a consensus analysts rating of 4.50.
Therefore, it is recommended to buy SBS.
- StrongBuy: 3
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SBS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 30.9 | 12% |
| Analysts Target Price | 30.9 | 12% |
SBS Fundamental Data Overview March 06, 2026
Market Cap BRL = 107.38b (20.40b USD * 5.2644 USD.BRL)
P/E Trailing = 15.0155
P/E Forward = 14.7493
P/S = 0.5886
P/B = 2.3603
P/EG = 0.4697
Revenue TTM = 41.21b BRL
EBIT TTM = 12.93b BRL
EBITDA TTM = 14.69b BRL
Long Term Debt = 28.92b BRL (from longTermDebt, last quarter)
Short Term Debt = 5.78b BRL (from shortTermDebt, last quarter)
Debt = 34.93b BRL (from shortLongTermDebtTotal, last quarter)
Net Debt = 29.96b BRL (from netDebt column, last quarter)
Enterprise Value = 137.61b BRL (107.38b + Debt 34.93b - CCE 4.69b)
Interest Coverage Ratio = 13.49 (Ebit TTM 12.93b / Interest Expense TTM 958.4m)
EV/FCF = 13.65x (Enterprise Value 137.61b / FCF TTM 10.08b)
FCF Yield = 7.33% (FCF TTM 10.08b / Enterprise Value 137.61b)
FCF Margin = 24.46% (FCF TTM 10.08b / Revenue TTM 41.21b)
Net Margin = 19.50% (Net Income TTM 8.03b / Revenue TTM 41.21b)
Gross Margin = 35.31% ((Revenue TTM 41.21b - Cost of Revenue TTM 26.66b) / Revenue TTM)
Gross Margin QoQ = 31.77% (prev 41.82%)
Tobins Q-Ratio = 1.43 (Enterprise Value 137.61b / Total Assets 95.99b)
Interest Expense / Debt = 0.46% (Interest Expense 161.9m / Debt 34.93b)
Taxrate = 33.40% (1.08b / 3.24b)
NOPAT = 8.61b (EBIT 12.93b * (1 - 33.40%))
Current Ratio = 0.86 (Total Current Assets 12.56b / Total Current Liabilities 14.53b)
Debt / Equity = 0.82 (Debt 34.93b / totalStockholderEquity, last quarter 42.71b)
Debt / EBITDA = 2.04 (Net Debt 29.96b / EBITDA 14.69b)
Debt / FCF = 2.97 (Net Debt 29.96b / FCF TTM 10.08b)
Total Stockholder Equity = 39.62b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.57% (Net Income 8.03b / Total Assets 95.99b)
RoE = 20.28% (Net Income TTM 8.03b / Total Stockholder Equity 39.62b)
RoCE = 18.86% (EBIT 12.93b / Capital Employed (Equity 39.62b + L.T.Debt 28.92b))
RoIC = 12.29% (NOPAT 8.61b / Invested Capital 70.07b)
WACC = 6.38% (E(107.38b)/V(142.31b) * Re(8.35%) + D(34.93b)/V(142.31b) * Rd(0.46%) * (1-Tc(0.33)))
Discount Rate = 8.35% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -81.65 | Cagr: -0.03%
[DCF] Terminal Value 86.74% ; FCFF base≈7.94b ; Y1≈9.80b ; Y5≈16.68b
[DCF] Fair Price = 554.0 (EV 417.89b - Net Debt 29.96b = Equity 387.93b / Shares 700.2m; r=6.38% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -56.47 | EPS CAGR: -50.64% | SUE: -1.01 | # QB: 0
Revenue Correlation: 79.64 | Revenue CAGR: 18.02% | SUE: 0.87 | # QB: 1
EPS next Year (2026-12-31): EPS=1.90 | Chg7d=+0.043 | Chg30d=+0.101 | Revisions Net=+2 | Growth EPS=+4.5% | Growth Revenue=+11.3%
P/E Trailing = 15.0155
P/E Forward = 14.7493
P/S = 0.5886
P/B = 2.3603
P/EG = 0.4697
Revenue TTM = 41.21b BRL
EBIT TTM = 12.93b BRL
EBITDA TTM = 14.69b BRL
Long Term Debt = 28.92b BRL (from longTermDebt, last quarter)
Short Term Debt = 5.78b BRL (from shortTermDebt, last quarter)
Debt = 34.93b BRL (from shortLongTermDebtTotal, last quarter)
Net Debt = 29.96b BRL (from netDebt column, last quarter)
Enterprise Value = 137.61b BRL (107.38b + Debt 34.93b - CCE 4.69b)
Interest Coverage Ratio = 13.49 (Ebit TTM 12.93b / Interest Expense TTM 958.4m)
EV/FCF = 13.65x (Enterprise Value 137.61b / FCF TTM 10.08b)
FCF Yield = 7.33% (FCF TTM 10.08b / Enterprise Value 137.61b)
FCF Margin = 24.46% (FCF TTM 10.08b / Revenue TTM 41.21b)
Net Margin = 19.50% (Net Income TTM 8.03b / Revenue TTM 41.21b)
Gross Margin = 35.31% ((Revenue TTM 41.21b - Cost of Revenue TTM 26.66b) / Revenue TTM)
Gross Margin QoQ = 31.77% (prev 41.82%)
Tobins Q-Ratio = 1.43 (Enterprise Value 137.61b / Total Assets 95.99b)
Interest Expense / Debt = 0.46% (Interest Expense 161.9m / Debt 34.93b)
Taxrate = 33.40% (1.08b / 3.24b)
NOPAT = 8.61b (EBIT 12.93b * (1 - 33.40%))
Current Ratio = 0.86 (Total Current Assets 12.56b / Total Current Liabilities 14.53b)
Debt / Equity = 0.82 (Debt 34.93b / totalStockholderEquity, last quarter 42.71b)
Debt / EBITDA = 2.04 (Net Debt 29.96b / EBITDA 14.69b)
Debt / FCF = 2.97 (Net Debt 29.96b / FCF TTM 10.08b)
Total Stockholder Equity = 39.62b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.57% (Net Income 8.03b / Total Assets 95.99b)
RoE = 20.28% (Net Income TTM 8.03b / Total Stockholder Equity 39.62b)
RoCE = 18.86% (EBIT 12.93b / Capital Employed (Equity 39.62b + L.T.Debt 28.92b))
RoIC = 12.29% (NOPAT 8.61b / Invested Capital 70.07b)
WACC = 6.38% (E(107.38b)/V(142.31b) * Re(8.35%) + D(34.93b)/V(142.31b) * Rd(0.46%) * (1-Tc(0.33)))
Discount Rate = 8.35% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -81.65 | Cagr: -0.03%
[DCF] Terminal Value 86.74% ; FCFF base≈7.94b ; Y1≈9.80b ; Y5≈16.68b
[DCF] Fair Price = 554.0 (EV 417.89b - Net Debt 29.96b = Equity 387.93b / Shares 700.2m; r=6.38% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -56.47 | EPS CAGR: -50.64% | SUE: -1.01 | # QB: 0
Revenue Correlation: 79.64 | Revenue CAGR: 18.02% | SUE: 0.87 | # QB: 1
EPS next Year (2026-12-31): EPS=1.90 | Chg7d=+0.043 | Chg30d=+0.101 | Revisions Net=+2 | Growth EPS=+4.5% | Growth Revenue=+11.3%